Selecta Biosciences, Inc. (NASDAQ:SELB) insider Earl Sands purchased 7,500 shares of the business’s stock in a transaction that occurred on Friday, November 17th. The shares were purchased at an average cost of $10.26 per share, with a total value of $76,950.00. Following the completion of the acquisition, the insider now directly owns 7,500 shares of the company’s stock, valued at $76,950. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Shares of Selecta Biosciences, Inc. (NASDAQ SELB) traded down $0.10 on Tuesday, hitting $10.13. 264,400 shares of the stock were exchanged, compared to its average volume of 111,464. The company has a debt-to-equity ratio of 0.32, a current ratio of 9.48 and a quick ratio of 9.48. Selecta Biosciences, Inc. has a fifty-two week low of $8.70 and a fifty-two week high of $28.00.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/earl-sands-purchases-7500-shares-of-selecta-biosciences-inc-selb-stock/1718303.html.

Several institutional investors and hedge funds have recently modified their holdings of the company. Nationwide Fund Advisors increased its stake in shares of Selecta Biosciences by 224.5% during the 2nd quarter. Nationwide Fund Advisors now owns 6,593 shares of the company’s stock worth $131,000 after purchasing an additional 4,561 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Selecta Biosciences by 1.8% during the third quarter. JPMorgan Chase & Co. now owns 365,138 shares of the company’s stock worth $7,131,000 after acquiring an additional 6,292 shares during the last quarter. New York State Common Retirement Fund boosted its position in Selecta Biosciences by 184.0% during the second quarter. New York State Common Retirement Fund now owns 12,500 shares of the company’s stock worth $248,000 after acquiring an additional 8,099 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Selecta Biosciences by 26.6% during the third quarter. Bank of New York Mellon Corp now owns 41,020 shares of the company’s stock worth $748,000 after acquiring an additional 8,620 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its position in Selecta Biosciences by 50.3% during the third quarter. Schwab Charles Investment Management Inc. now owns 29,600 shares of the company’s stock worth $541,000 after acquiring an additional 9,900 shares during the last quarter. 53.13% of the stock is owned by institutional investors and hedge funds.

A number of research analysts have issued reports on SELB shares. Zacks Investment Research raised shares of Selecta Biosciences from a “hold” rating to a “buy” rating and set a $10.00 target price for the company in a report on Saturday, November 11th. Canaccord Genuity reaffirmed a “buy” rating and issued a $30.00 target price on shares of Selecta Biosciences in a report on Tuesday, November 7th. ValuEngine cut shares of Selecta Biosciences from a “hold” rating to a “sell” rating in a report on Tuesday, September 26th. Finally, UBS AG cut shares of Selecta Biosciences from a “buy” rating to a “neutral” rating in a report on Thursday, November 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. Selecta Biosciences has a consensus rating of “Buy” and an average target price of $25.20.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.

Insider Buying and Selling by Quarter for Selecta Biosciences (NASDAQ:SELB)

Receive News & Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.